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Abstract: Marine invertebrates are rich sources of bioactive compounds and their 
biotechnological potential attracts scientific and economic interest worldwide. Although 
sponges are the foremost providers of marine bioactive compounds, cnidarians are also 
being studied with promising results. This diverse group of marine invertebrates includes 
over 11,000 species, 7500 of them belonging to the class Anthozoa. We present an 
overview of some of the most promising marine bioactive compounds from a therapeutic 
point of view isolated from cnidarians in the first decade of the 21st century. Anthozoan 
orders Alcyonacea and Gorgonacea exhibit by far the highest number of species yielding 
promising compounds. Antitumor activity has been the major area of interest in the 
screening of cnidarian compounds, the most promising ones being terpenoids 
(monoterpenoids, diterpenoids, sesquiterpenoids). We also discuss the future of 
bioprospecting for new marine bioactive compounds produced by cnidarians. 
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1. Introduction 
In terms of biodiversity, marine environments are among the richest and most complex ecosystems. 
Harsh chemical and physical conditions in the environment have been important drivers for the 
production of a variety of molecules with unique structural features. These marine molecules exhibit 
various types of biological activities [1], with compounds of high economic interest having potential 
applications in the pharmaceutical and medical sectors. Although nearly 20,000 compounds have been 
discovered since the field of marine bioactive compound biochemistry began in the mid-1960s, only a 
very limited number have seen industrial application. It has been clear since marine bioprospecting 
began that the world’s oceans and their diverse biota represent a significant resource, perhaps the 
greatest resource on Earth, for the discovery of new bioactive compounds. Early National Cancer 
Institute (NCI) programs in the USA demonstrated that marine invertebrates were a superb source of 
potential lead molecules. The decisive boost to this new age of bioprospecting was provided by the 
NCI when it was found that bioassays with marine organism extracts were far more likely to yield 
anticancer drugs than terrestrial sources [2]. In this way, it is not surprising that over the past 40 years 
major advances in the discovery of marine drugs have been recorded in clinical trials for cancer [3]. 
Apart from anticancer activity, these compounds have proven to be an abundant source of 
pharmacologically active agents for the production of therapeutic entities [4] against AIDS, 
inflammatory conditions and microbial diseases. 
Marine bioactive compounds display varied potential applications, namely as molecular tools, in 
cosmetics, as fine chemicals, as nutraceuticals and in agrochemical industries [5]. 
Although only a few marine-derived products are currently on the market (e.g., Prialt® and 
Yondelis®), several new compounds are now in the clinical pipeline and several more are in clinical 
development. The few approvals so far for the commercialization of drugs from the sea have not been 
due to a lack of discovery of novel marine bioactive compounds, but because of the complexity of 
issues raised upon the development of these products [4]. Faulkner [6–20], Blunt et al. [21–29], and 
Mayer [30–38] have provided extensive reviews on the total number of marine natural products 
(MNPs) discovered over the last 25 years, the most promising ones being produced by marine 
invertebrates. Sponges (phylum Porifera) have long been recognized as the most interesting group of 
marine invertebrates for the discovery of new drugs [5,39,40]. However, with growing bioprospecting 
efforts and the screening of previously unexplored marine habitats, the biotechnological potential of 
other groups of marine invertebrates has also started to attract the attention of researchers. The ability 
of cnidarians (such as jellyfish, sea anemones and corals) to produce powerful toxins and venoms [41] 
has been well documented. However, further research has demonstrated that MNPs produced by 
cnidarians are more than toxins and venoms. The phylum Cnidaria is a large, diverse and ecologically 
important group of marine invertebrates that includes over 11,000 extant species [42]. Over 3000 MNPs 
have been described from this phylum alone, mostly in the last decade. 
In this work, we present an overview of the most promising marine bioactive compounds isolated 
from cnidarians in the first decade of the 21st century, which may have applications in the therapy of 
human diseases. The present study also discusses future perspectives for the bioprospecting of new 
MNPs produced by this speciose group of marine invertebrates. 
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2. Methodology 
The most relevant peer reviewed literature published during the first decade of the 21st century 
covering MNPs was surveyed for the present work [18–37]. During this period alone, over 
2000 molecules from cnidarians were described. In order to focus our study and address only those 
compounds displaying a high potential for industrial applications, we have decided to use as guidelines 
the values of IC50 (half maximal inhibitory concentration). IC50 is a quantitative measure which 
indicates how much of a particular substance (inhibitor) is needed to inhibit a given biological process 
or component of a process by half. It is important to highlight that the NCI has renamed the IC50 to 
GI50 [43] in order to emphasize the correction for cell count at time zero in cancer cells; in this way, 
some results on this quantitative measure are now also presented under these directives. Additionally, 
the ED50 (the median dose that produces the desired effect of a drug in half the test population) was 
also used to identify promising marine bioactive compounds produced by cnidarians. Only the 
compounds displaying an IC50 ≤ 10.0 µg/mL or µM (except where stated otherwise) and ED50 ≤ 4.0 µg/mL 
were considered for the present study, as these values are commonly used in the surveyed literature to 
ascertain relevant bioactivity (e.g., [44,45]). In the few cases were neither IC50 nor ED50 values were 
described for a MNP in a manuscript, that compound was selected to be part of the present survey only 
if either the authors of that manuscript, or those citing that manuscript, clearly stated that the results 
recorded were highly promising for industrial applications. All species producing the compounds 
selected for the present work were grouped into classes and orders of phylum Cnidaria (Table 1) 
(according to the classification proposed in the World Register of Marine Species (WoRMS)) [46].  
Table 1. Classes and orders in the phylum Cnidaria followed in this paper. 
Phylum Class Order 
Cnidaria 
(≈11,287 species) 
Anthozoa (≈7500 species) 
Actiniaria 
Antipatharia 
Ceriantharia 
Corallimorpharia 
Scleractinia 
Zoanthidea 
Alcyonacea 
Gorgonacea 
Helioporacea 
Pennatulacea 
Cubozoa (≈36 species) Carybdeida Chirodropida 
Hydrozoa (≈3500 species) 
Anthoathecata 
Leptothecata 
Siphonophorae 
Actinulida 
Limnomedusae 
Narcomedusae 
Trachymedusae 
Polypodiozoa (1 species) 
Scyphozoa (≈200 species) Coronatae Rhizostomeae Semaeostomeae 
Staurozoa (≈50 species) Stauromedusae 
This approach allowed us to identify which taxonomic groups of cnidarians screened so far display 
the highest potential to yield new drugs or pharmacological products derived from marine bioactive 
compounds. Nonetheless, it is important to highlight that cnidarian species identification is a 
challenging task and it is possible that some of the species (or even genera) referred to in the scientific 
literature may not be correct [47]. In this way, it is of paramount importance that in future works the 
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authors addressing marine bioactive compounds produced by cnidarians provide a detailed description 
on how target species have been identified. 
3. Class Anthozoa 
Class Anthozoa currently includes 10 orders and over 7500 valid species (about 2/3 of all known 
cnidarian species) (Table 1). Within the Anthozoa, the order Alcyonacea (soft corals) and Gorgonacea 
(sea fans) are the ones which have contributed with the highest number of promising bioactive marine 
compounds, although other orders, such as Actiniaria (sea anemones) and Scleractinia (hard corals), 
have also yielded relevant compounds [48–51]. 
3.1. Order Alcyonacea (Soft Corals) 
Soft corals are generally brightly colored and rich in nutritionally important substances. However, 
the incidence of predation in the majority of these organisms is low due to the toxic compounds they 
produce to deter predators [52]. Several biosynthetic studies have been carried out on the metabolites 
of soft corals [53] and some of those compounds have already shown to have great potential for the 
development of new pharmaceuticals and antifoulants. Table 2 summarizes the most promising 
compounds from order Alcyonacea (class Anthozoa) described in the present review. 
Table 2. Most promising compounds studied in the last decade from cnidarian species in 
order Alcyonacea (soft corals), class Anthozoa. 
Family and Species Drug Class Compound Chemistry Country Ref.  
Alcyoniidae 
Klyxum simplex Anti-inflammatory Simplexin E Diterpenoid TAIW [54] 
Klyxum simplex Antitumor Klysimplexin B and H Diterpenoid TAIW [55] 
Lobophytum sp. Antitumor Lobophytene Diterpenoid VN [56] 
Lobophytum sp. Anti-HIV Lobohedleolide Diterpenoid PHL [57] 
Lobophytum sp. Anti-HIV (7Z)-lobohedleolide, Diterpenoid PHL [57] 
Lobophytum sp. Anti-HIV 17-dimethylamino lobohedleolide Diterpenoid PHL [57] 
Lobophytum crassum Anti-inflammatory Crassumolides A and C Terpenoid TAIW [58] 
Lobophytum cristagalli Antitumor Cembranolide diterpene Diterpenoid RSC [59] 
Lobophytum durum Anti-inflammatory Durumolides A–C Terpenoid TAIW [60] 
Lobophytum durum Anti-inflammatory Durumhemiketalolide A–C Cembranoid TAIW [61] 
Sarcophyton crassocaule Antitumor Crassocolides H–M Cembranoid TAIW [62] 
Sinularia sp. Antiulcer Sinulide Spermine  [63] 
Sinularia sp. Antimicrobial Lipids Polyketide RUS [64] 
Sinularia flexibilis Antitumor Flexilarin D Cembranoid TAIW [65] 
Sinularia flexibilis Antifoulant 11-episinulariolide Diterpenoid AUS [66] 
Sinularia gibberosa Anti-inflammatory Gibberoketosterol Steroid TAIW [67] 
Sinularia querciformis Anti-inflammatory Querciformolide C Terpenoid TAIW [68] 
Clavulariidae 
Clavularia sp. Nervous system Stolonidiol Diterpenoid JPN [69] 
Clavularia koellikeri Antitumor Cembrane-type diterpenoid Diterpenoid JPN [70] 
Clavularia viridis Antitumor Claviridic acid Prostanoid TAIW [71] 
Clavularia viridis Antitumor Clavulones Prostanoid TAIW [71] 
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Table 2. Cont. 
Clavularia viridis Antitumor Claviridenone Prostanoid TAIW [45] 
Clavularia viridis Antitumor Halogenated prostanoids Prostanoid JPN [72] 
Clavularia viridis Antitumor Bromovulone III Prostanoid TAIW [73,74] 
Clavularia viridis Antitumor Yonarasterols Steroid JPN [75] 
Clavularia viridis Antitumor Stoloniferone E Steroid TAIW [45] 
Telesto riisei Antitumor Punaglandins Prostaglandin USA [76] 
Nephtheidae 
Dendronephthya sp. Antifoulant Isogosterones A–D Steroid JPN [77] 
Dendronephthya rubeola Antitumour Capnell-9(12)-ene-8β,10α-diol Sesquiterpenoid DE [78,79,80]
Nephthea chabroli Antitumor Chabranol Terpenoid TAIW [81] 
Nephthea erecta Anti-inflammatory Ergostanoids 1 and 3 Ergostanoid TAIW [82] 
Xeniidae 
Asterospicularia laurae Antitumor Asterolaurin A Diterpenoid TAIW [83] 
Cespitularia hypotentaculata Antitumor Cespitularin C Diterpenoid TAIW [84] 
Xenia novaebritanniae Antibacterial Xeniolide I Diterpenoid ISR [85] 
Xenia plicata Antitumor Blumiolide C Diterpenoid TAIW [44] 
AUS: Australia; DE: Germany; ISR: Israel; JPN: Japan; PHL: Philippines; RSC: Republic of Seychelles; RUS: Russia; 
TAIW: Taiwan; VN: Vietnam.  
Soft corals are rich sources of secondary metabolites such as diterpenes, sesquiterpenes, 
furanoditerpenes, terpenoids, capnellenes and steroids (e.g., Lobophytum, Sinularia (Figure 1A), 
Sarcophyton [86] (Figure 1C), Capnella [87], Dendronephthya [78]), that have shown to  
display HIV-inhibitory [57], cytotoxic [88,89], anti-inflammatory [90,91], anticancer [92,93] and 
antimicrobial activity [94], as well as cardiac and vascular responses [95]. Soft corals of the family 
Nephtheidae are known for their content of sesquiterpenes and particularly capnellenes [28]. Some 
sesquiterpenes isolated from Capnella imbricate [87,96–98] showed anti-inflammatory activity and a 
dihydroxycapnellene (capnell-9(12)-ene-8β,10α-diol) from Dendronephthya rubeola demonstrated a 
good antiproliferative activity against murine fibroblasts cell line (L-929, GI50 6.8 µM/L) and a good 
cytotoxicity against cancer cell lines implicated in human leukemia (K-562, IC50 0.7 µM) and  
human cervix carcinoma (HeLa, IC50 7.6 µM) [78]. Capnell-9(12)-ene-8β,10α-diol strongly inhibits 
the interaction of the oncogenic transcription factor Myc with its partner protein Max [79,80], making 
it a therapeutically interesting compound in oncology [78]. Nephthea chabroli also produces a  
nor-sisquiterpene compound, chabranol, which displays moderate cytotoxicity against P-388 (mouse 
lymphocytic leukemia cells) with an ED50 1.81 µg/mL [81]. Nephthea erecta produces two proteins in 
mediated inflammatory responses, the oxygenated ergostanoids 1 and 3. These compounds at a 
concentration of 10 µM significantly reduced the levels of the iNOS (inducible nitric oxide synthase) 
(45.8 ± 9.9 and 33.6 ± 20.6%, respectively) and COX-2 (cyclooxygenase-2) protein (68.1 ± 2.3 and 
10.3 ± 6.2%, respectively), when compared with the control cells stimulated with lipopolysaccharides 
(LPS) [82].  
Species in the genus Xenia (family Xeniidae) (Figure 1B) are a rich source of diterpenoids. 
Xeniolides I, isolated from Xenia novaebrittanniae demonstrated antibacterial activity at a 
concentration of 1.25 mg/mL in Escherichia coli ATCC and Bacillus subtilis [85]. Blumiolide C, a 
diterpenoid from the Xenia blumi (presently accepted as Xenia plicata), exhibited potent cytotoxicity 
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against mouse lymphocytic leukemia (P-388, ED50 0.2 µg/mL) and human colon adenocarcinoma 
(HT-29, ED50 0.5 µg/mL) cells [44]. 
Figure 1. Some cnidarians addressed in this review (all images by Ricardo Calado).  
(A) Sinularia sp.; (B) Xenia sp.; (C) Sarcophyton sp.; (D) Briareum sp.  
 
Polyoxygenated cembranoids, crassocolides H–M from Sarcophyton crassocaule, demonstrated 
cytotoxicity against cancer cell lines of human medulloblastoma (Daoy cells) where crassocolides I 
and M were found to be more active (IC50 0.8 and 1.1 μg/mL, respectively). Crassocolide H was also 
found to inhibit the growth of human oral epidermoid carcinoma (KB) cells (IC50 5.3 μg/mL) and 
crassocolide L active against human cervical epitheloid carcinoma (HeLa) cells (IC50 8.0 μg/mL) [62]. 
Another example of a potential new therapeutic anticancer agent is a cembranolide diterpene from 
Lobophytum cristagalli, which has shown a potent inhibitory activity (IC50 0.15 μM) [59] over farnesyl 
protein transferase (FPT, an important protein in signal transduction and regulation of cell 
differentiation and proliferation [99]). This type of FPT inhibition enhanced interest in this group  
of metabolites [86]. Other species of this genus also showed cembranolide diterpenes (lobophytene) 
with significant cytotoxic activity against human lung adenocarcinoma (A549) and human colon 
adenocarcinoma (HT-29) cell lines [56]. Lobophytum durum and Lobophytum crassum produce 
durumolides A–C [60], durumhemiketalolide A–C [61] and crassumolides A and C [58], with  
anti-inflammatory effects. They have been shown to inhibit up-regulation of the pro-inflammatory 
iNOS and COX-2 proteins in LPS-stimulated murine macrophage cells at IC50 < 10 µM [58,60]. The 
diterpenoids, lobohedleolide, (7Z)-lobohedleolide, and 17-dimethylaminolobohedleolide, were isolated 
from the aqueous extract of Lobophytum species and exhibited moderate HIV-inhibitory activity  
(IC50 approximately 7–10 μg/mL) in a cell-based in vitro anti-HIV assay [57]. 
Klyxum simplex produces diterpene compounds, such as simplexin E, which at a concentration of 
10 μM was found to considerably reduce the levels of iNOS and COX-2 proteins to 4.8 ± 1.8% and 
37.7 ± 4.7%, respectively. These results have shown that this compound significantly inhibits the 
accumulation of the pro-inflammatory iNOS and COX-2 proteins in LPS-stimulated RAW264.7 
macrophage cells [54]. This species also produces two diterpene compounds, klysimplexins B and H, 
exhibiting moderate cytotoxicity towards human carcinoma cell lines. Klysimplexin B exhibits 
B 
DA C
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cytotoxicity toward human hepatocellular carcinoma (Hep G2 and Hep 3B), human breast carcinoma 
(MDA-MB-231 and MCF-7), human lung carcinoma (A549) and human gingival carcinoma (Ca9-22) 
cell lines with IC50’s of 3.0, 3.6, 6.9, 3.0, 2.0, and 1.8 μg/mL, respectively. Metabolite klysimplexin H 
demonstrated cytotoxicity (IC50’s 5.6, 6.9, 4.4, 5.6, 2.8 and 6.1 μg/mL) toward human hepatocellular 
carcinoma (Hep G2 and Hep 3B), human breast carcinoma (MDA-MB-231 and MCF-7), human lung 
carcinoma (A549) and human gingival carcinoma (Ca9-22) cell lines, respectively [55]. 
In Sinularia sp. (Figure 1A), a tetraprenylated spermine derivative has been isolated—sinulamide—
which revealed an H,K-ATPase inhibitory activity. H,K-ATPase is a gastric proton pump of stomach 
and is the enzyme primarily responsible for the acidification of the stomach contents. Its inhibition is a 
very common clinical intervention used in diseases including dyspepsia, peptic ulcer, and gastroesophageal 
reflux (GORD/GERD). Sinulide is a potential antiulcer drug, as it inhibits production of gastric acid by 
H,K-ATPase (IC50 5.5 μM) [63]. Although it has been synthesized [100], no clinical trials seem to 
have been reported. The steroid gibberoketosterol [67], isolated from Sinularia gibberosa, and the 
diterpenoid querciformolide C [68] from Sinularia querciformis, showed significant inhibition of the 
up-regulation of the pro-inflammatory iNOS and COX-2 proteins in LPS-stimulated murine 
macrophages at concentration <10 μM [67,68]. Paralemnalia thyrsoides showed significant inhibition 
of pro-inflammatory iNOS protein expression (70% at IC50 10 µM) [101]. Sinularia species produce 
significant molecules: lipids from Sinularia grandilobata and another unspecified species of  
Sinularia possesses antibacterial and antifungal activity [64]. The diterpene 11-episinulariolide from 
Sinularia flexibilis is an interesting antifoulant exhibiting strong algacidal properties [66]. This species 
also produces cembrenoids, named flexilarins, which evidence cytotoxic activity in cancer cell lines. 
Flexilarin D exhibited potent cytotoxicity in human hepatocarcinoma (Hep2) cells with IC50 0.07 μg/mL, 
and moderate cytotoxic activity against human cervical epitheloid carcinoma (HeLa, IC50 0.41 μg/mL), 
human medulloblastoma (Daoy, 1.24 μg/mL) and human breast carcinoma (MCF-7, 1.24 μg/mL) 
cell lines [65]. 
Antifouling agents from natural sources are of increasing interest since the International Maritime 
Organization (IMO) banned the use of certain antifouling agents, such as tri-n-butyltin (TBT), due to 
the ecological impacts of these biocides in the marine environment. Several studies have demonstrated 
that soft corals can yield large quantities of promising antifouling metabolites [102,103]. In fact,  
17.95% of potential antifouling natural compounds are from cnidarians (e.g., soft coral) [104]. One of 
the most promising natural antifouling agent identified so far is an isogosterone isolated from an 
unspecified Dendronephthya [77]. 
The genus Clavularia contains secondary metabolites with unique structures and remarkable biological 
activities. Some of the species in this genus produce prostanoids (icosanoids) [45,72,73,105,106], 
steroids [75] and diterpenoids [70,107]. The bioactive marine diterpene, stolonidiol, isolated from an 
unidentified Clavularia, showed potent choline acetyltransferase (ChAT) inducible activity in primary 
cultured basal forebrain cells and clonal septal SN49 cells, suggesting that it may act as a potent 
neurotrophic factor-like agent on the cholinergic nervous system [69]. Cholinergic neurons in the basal 
forebrain innervate the cortex and hippocampus, and their function may be closely related to cognitive 
function and memory. The degeneration of neuronal cells in this brain region is considered to be 
responsible for several types of dementia including Alzheimer’s disease. One of the neurotransmitters, 
acetylcholine, is synthesized from acetyl coenzyme A and choline by the action of ChAT. Therefore, 
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induction of ChAT activity in cholinergic neurons may improve the cognitive function in diseases 
exhibiting cholinergic deficits [108–110]. 
Prostanoids (claviridic acid) isolated from Clavularia viridis exhibited potent inhibitory effects  
on phytohemagglutinin-induced proliferation of peripheral blood mononuclear cells (PBMC, 
5 μg/mL), as well as significant cytotoxic activity against human gastric cancer cells (AGS, IC50  
1.73–7.78 μg/mL) [71]. Claviridenone extracts also showed potent cytotoxicity against mouse 
lymphocytic leukemia (P-388) and human colon adenocarcinoma (HT-29), and exceptionally potent 
cytotoxicty against human lung adenocarcinoma (A549) cells, with ED50 between 0.52 pg/mL and 
1.22 μg/mL [45]. Halogenated prostanoids also showed cytotoxic activity against human T lymphocyte 
leukemia cells (MOLT-4, IC50 0.52 µg/mL), human colorectal adenocarcinoma (DLD-1, IC50 0.6 µg/mL) 
and human diploid lung fibroblast (IMR-90, IC50 4.5 µg/mL) cells [72]. The cyclopentenone 
prostanoid, bromovulone III-a promising marine natural compound for treatment of prostate, colon and 
hepatocellular carcinoma-showed anti-tumor activity against human prostate (PC-3) and human colon 
(HT29) cancer cells at an IC50 of 0.5 µM [73], and induced apoptotic signaling in a sequential manner 
in Hep3B cells [74]. In the case of prostate cancer cells, this compound displayed an anti-tumor 
activity 30 to 100 times more effective than cyclopentenone prostaglandins (known to suppress tumor 
cell growth and to induce apoptosis in prostate cancer cells), by causing a rapid redistribution and 
clustering of Fas (member of the tumor necrosis factor (TNF) receptor superfamily). Apoptotic 
stimulation of Fas by specific ligand or antibodies causes the formation of a membrane-associated 
complex comprising Fas clustering) in PC-3 cells [111]. C. viridis also produces steroids that show 
cytotoxic activity against human colorectal adenocarcinoma (DLD-1, 0.02 < IC50 < 50 µg/mL) and 
also against human T lymphocyte leukemia cells (MOLT-4, 0.01 < IC50 < 10 µg/mL), in the case of 
yonarasterols [75]. Stoloniferone additionally displayed potent cytotoxicity against mouse lymphocytic 
leukemia (P-388), human colon adenocarcinoma (HT-29) and human lung adenocarcinoma (A549) 
cells [45]. This species produces several compounds with anti-tumor activity in different types of 
human tumors, although more in vitro studies are needed to determine which compound are potential 
anticancer agents. Clavularia koellikeri produces diterpenoids as secondary metabolites, which display 
cytotoxic activity against human colorectal adenocarcinoma (DLD-1, IC50 4.2 µg/mL) and strong 
growth inhibition against human T lymphocyte leukemia cells (MOLT-4, IC50 0.9 µg/mL) [70]. 
In the genus Cespitularia, several interesting diterpenes of cembrane and neodolabellane skeletons 
have been identified. In Cespitularia hypotentaculata (family Xeniidae) a significant production of 
diterpenoids was detected. Cespitularin C exhibited potent cytotoxicity against mouse lymphocytic 
leukemia (P-388, ED50 0.01 µg/mL) and human lung adenocarcinoma (A549, ED50 0.12 µg/mL) cells, 
while cespitularin E exhibited potent cytotoxicity against human lung adenocarcinoma (A549, ED50 
0.034 µg/mL) cell cultures [84]. A less active diterpene, Asterolaurin A, from Asterospicularia laurae (a 
species from the same family) exhibited cytotoxicity against human hepatocellular carcinoma (HepG2) 
cells with an IC50 8.9 µM [83]. 
Telesto riisei produces punaglandins, highly functional cyclopentadienone and cyclopentenone 
prostaglandins. Cyclopentenone prostaglandins have unique antineoplastic activity and are potent 
growth inhibitors in a variety of cultured cells. These punaglandins have been shown to inhibit  
P53 accumulation (a tumor suppressor protein) and ubiquitin isopeptidase activity (IC50 between  
0.04 and 0.37 µM) (enzyme involved in protein degradation system) in vitro and in vivo [76]. Since 
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these proteasome inhibitors exhibit higher antiproliferative effects than other prostaglandins [112], 
they may represent a new class of potent cancer therapeutics. 
3.2. Order Gorgonacea (Sea Fans) 
Gorgonians are a well-known source of compounds exhibiting significant biological activity [113]. 
Table 3 summarizes the most promising compounds from order Gorgonacea (class Anthozoa) 
described in the present review. Studies on Isis hippuris have resulted in the isolation of a series of 
novel metabolites such as sesquiterpenes [114], steroids [115], A-nor-hippuristanol [116] and 
isishippuric acid B [116]. These compounds exhibit potent cytotoxicity against cancer cell lines of 
human hepatocellular carcinoma (HepG2 and Hep3B, IC50 0.08–4.64 µg/mL and 0.10–1.46 µg/mL, 
respectively) [116,117], human breast carcinoma (MCF-7, IC50 0.20–4.54 µg/mL and MDA-MB-231, 
IC50 0.13–2.64 µg/mL) [117], mouse lymphocytic leukemia (P-388), human lung adenocarcinoma 
(A549), and human colon adenocarcinoma (HT-29) with ED50 values less than 0.1 µg/mL [115,116] 
and IC50 of 0.1 µg/mL [114]. 
Table 3. Most promising compounds studied in the last decade from cnidarian species in 
order Gorgonacea (sea fans), class Anthozoa. 
Family and Species Drug Class Compound Chemistry Country Ref.  
Briareidae 
Briareum excavate Anti-inflammatory Briaexcavatin E Diterpenoid TAIW [118] 
Briareum excavate Antitumor Briaexcavatolides L and P Diterpenoid TAIW [119] 
Briareum asbestinum Antimalarial Briarellin D, K and L Diterpenoid PAN, USA [120] 
Ellisellidae 
Junceella fragilis Anti-inflammatory Frajunolides B and C Terpenoid TAIW [121] 
Junceella juncea Antifoulant Juncin ZII Diterpenoid TAIW [122] 
Gorgoniidae 
Leptogorgia setácea Antifoulant Homarine Pyridine GEO [123] 
Leptogorgia virgulata Antifoulant Homarine Pyridine GEO [123] 
Leptogorgia virgulata Antifoulant Pukalide Diterpenoid USA [124] 
Leptogorgia virgulata Antifoulant Epoxypukalide Diterpenoid USA [124] 
Pseudopterogorgia sp. Antitumor Secosterols Sterol USA [125] 
Pseudopterogorgia sp. Anti-inflammatory Secosterols Sterol USA [125] 
Pseudopterogorgia acerosa Antitumor Bis(pseudopterane) amine Dialkylamine BHS [126] 
Pseudopterogorgia bipinnata Antituberculosis Bipinnapterolide B Terpenoid USA [127] 
Pseudopterogorgia bipinnata Antimalarial Caucanolide A and D Diterpenoid COL, PAN, USA [128] 
Pseudopterogorgia elisabethae Antimicrobial Pseudopterosin X Diterpenoid USA [129] 
Pseudopterogorgia elisabethae Antituberculosis Ileabethoxazole Diterpenoid USA [130] 
Pseudopterogorgia elisabethae Antituberculosis Homopseudopteroxazole Diterpenoid USA [131] 
Pseudopterogorgia elisabethae Antituberculosis Caribenols A and B Terpenoid USA [132] 
Pseudopterogorgia elisabethae Antituberculosis Elisapterosin B Diterpenoid USA [133] 
Pseudopterogorgia elisabethae Antimalarial Aberrarone Diterpenoid COL [134] 
Pseudopterogorgia kallos Antimalarial Bielschowskysin Diterpenoid PAN, USA [135] 
Pseudopterogorgia kallos Antitumor Bielschowskysin Diterpenoid PAN, USA [135] 
Pseudopterogorgia rígida Antimicrobial Curcuphenol Terpenoid USA [136] 
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Table 3. Cont. 
Isididae 
Isis hippuris Antitumor Suberosenol B Terpenoid TAIW [114] 
Isis hippuris Antitumor Polyoxygenated steroids Steroid IND [115,117]
Isis hippuris Antitumor A –nor-hippuristanol Steroid TAIW [116] 
Isis hippuris Antitumor Isishippuric acid B Steroid TAIW [116] 
Plexauridae 
Eunicea sp. Antimalarial Sesquiterpenoids Sesquiterpenoid COL, PAN, USA [137] 
Eunicea fusca Anti-inflammatory Fuscisides Diterpenoid USA [138] 
Euplexaura flava Anti-inflammatory Butenolide Lipid JPN [139] 
ND: Not Determined; BHS: Bahamas; COL: Colombia; GEO: Georgia; IND: Indonesia; PAN: Panama; TAIW: Taiwan; 
USA: United States of America. 
Species from the genus Pseudopterogorgia are a rich source of unusual biologically active diterpenoids, 
sesquiterpenes, and polyhydroxylated steroids, which exhibit diverse structures [127,140,141]. A 
sample of the organic extract of Pseudopterogorgia bipinnata was included in an initial screening 
carried out as part of an effort in the discovery of new antimalarial agents. This extract was found to be 
active in inhibiting the growth of Plasmodium falciparum (a protozoan parasite responsible for the 
most severe forms of malaria). Caucanolide A and D demonstrated significant in vitro antiplasmodial 
activity against chloroquine-resistant P. falciparum W2 (IC50 17 µg/mL and IC50 15 µg/mL, 
respectively) [128]. Three secosterols isolated from an unidentified gorgonian from genus 
Pseudopterogorgia inhibited human protein kinase C (PKC) α, βI, βII, γ, δ, ε, η, and ζ, with IC50 
values in the range 12–50 μM [125]. PKC is a key player in cellular signal transduction and has been 
implicated in cancer, cardiovascular and renal disorders, immunosuppression, and autoimmune diseases 
such as rheumatoid arthritis [99]. Semisynthetic derivatives also showed a similar activity [125]. 
Promising antimicrobial substances were also reported from Pseudopterogorgia rigida (e.g., 
curcuphenol) [136] and from Pseudopterogorgia elisabethae (e.g., pseudopterosin X and Y) [129]. 
Ileabethoxazole, homopseudopteroxazole, caribenols A and B and elisapterosin B from P. elisabethae 
and bipinnapterolide B from P. bipinnata inhibit Mycobacterium tuberculosis H37Rv at a concentration 
of 12.5 µg/mL [131,133] (for elisapterosin B and homopseudopteroxazole) and at a concentration 
range of 128–64 µg/mL [130,132,142] (for others compounds). In fact, the inhibition of M. tuberculosis 
H37Rv is within the ranges recorded for rifampin [130]. P. elisabethae and P. bipinnata also produce 
antituberculosis compounds. Bielschowskysin, a naturally occurring diterpene isolated from 
Pseudopterogorgia kallos [135] and aberrarone isolated from P. elisabethae [134] exhibited 
antiplasmodial activity (IC50 10 μg/mL) when tested against P. falciparum. The first compound was 
also found to display strong and specific in vitro cytotoxicity against the EKVX non-small cell lung 
cancer (GI50 < 0.01 μM) and CAKI-1 renal cancer (GI50 0.51 μM) [135]. Bis(pseudopterane) amine 
from Pseudopterogorgia acerosa was found to exhibit selective activity against HCT116 (IC50 4 μM) 
cell lines [126]. 
Fuscosides, originally isolated from Eunicea fusca [138], selectively and irreversibly inhibited 
leukotriene synthesis. Leukotrienes are molecules of the immune system that contribute to inflammation 
in asthma and allergic rhinitis and its production is usually related to histamine release [143]. 
Pharmacological studies indicated that fuscoside B inhibits the conversion of arachidonic acid (AA) to 
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leukotriene B4 and C4 (LTB4 and LTC4) [138,144] by inhibiting the 5-Lipoxygenase (5-LO), in the 
case of LTB4 with an IC50 of 18 μM [144]. These selective inhibitors of lipoxygenase isoforms can  
be useful as pharmacological agents, as nutraceuticals or as molecular tools [99]. Sesquiterpenoids 
metabolites isolated from Eunicea sp. display antiplasmodial activity against the malaria parasite  
P. falciparum W2 (chloroquine-resistant) strain, with IC50 values ranging from 10 to 18 µg/mL [137]. 
The gorgonian Junceella fragilis produces secondary metabolites, frajunolides B and C, with  
anti-inflammatory effects towards superoxide anion generation and elastase release by human 
neutrophils, with an IC50 > 10 µg/mL [121]. When properly stimulated, activated neutrophils secrete a 
series of cytotoxins, such as the superoxide anion (O2•−), a precursor of other reactive oxygen species 
(ROS), granule proteases, and bioactive lipids [145,146]. The production of the superoxide anion is 
linked to the killing of invading microorganisms, but it can also directly or indirectly damage 
surrounding tissues. On the other hand, neutrophil elastase is a major secreted product of stimulated 
neutrophils and a major contributor to the destruction of tissue in chronic inflammatory disease [147]. 
The anti-inflammatory butenolide lipide [148] from the gorgonian Euplexaura flava [139] can be currently 
synthesized, opening the possibility of advancing into a new level of anti-inflammatory pharmaceuticals. 
Some of the most interesting compounds identified so far in the on-going search for new  
anti-fouling agents have been recorded in the order Gorgonacea. Good examples of such compounds 
are juncin ZII from Junceella juncea [122], homarine from Leptogorgia virgulata and  
Leptogorgia setacea [123], pukalide and epoxypukalide recorded so far only from L. virgulata [124]. 
Species of genus Briareum (family Briareidae) (Figure 1D) (which commonly exhibit an incrusting 
appearance rather than the fan-like shape of many gorgonians) are widely abundant in Indo-Pacific and 
Caribean coral reefs. These organisms have been recognized as a valuable source of bioactive 
compounds with novel structural features. Briarane-related natural products are a good example of 
such promising compounds due to their structural complexity and biological activity [149,150]. 
Briaexcavatin E, from Briareum excavata (Nutting 1911), also occasionally referred to as 
Briarium excavatum, inhibited human neutrophil elastase (HNE) release with an IC50 between 5 and 
10 µM [118]. Briaexcavatolides L and P, diterpenoids from the same species exhibited significant 
cytotoxicity against mouse lymphocytic leukemia (P-388) tumor cells with ED50 of 0.5 [119] and 
0.9 μg/mL [151], respectively. Diterpenoids produced from Briareum polyanthes (presently accepted 
as Briareum asbestinum), namely Briarellin D, K and L, exhibited antimalarial activity against 
P. falciparum with an IC50 between 9 and 15 µg/mL [120]. 
3.3. Other Orders 
Sea anemones (order Actiniaria) are a rich source of biologically-active proteins and polypeptides. 
Several cytolytic toxins, neuropeptides and protease inhibitors have been identified from them [48]. In 
addition to several equinatoxins, potent cytolytic proteins and an inhibitor of papain-like cysteine 
proteinases (equistatin), were isolated from the sea anemone Actinia equina [152]. Equistatin has been 
shown to be a very potent inhibitor of papain and a specific inhibitor of the aspartic proteinase 
cathepsin D [153]. While papain-like cysteine proteases have been implicated in various diseases of 
the central nervous system, such as brain tumors, Alzheimer’s disease, stroke, cerebral lesions, 
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neurological autoimmune diseases and certain forms of epilepsy [154], aspartic proteinase cathepsin D 
is involved in the pathogenesis of breast cancer [155] and possibly Alzheimer’s disease [156].  
Cycloaplysinopsin C, a bis(indole) alkaloid isolated from Tubastrea sp. (order Scleractinia), was 
found to inhibit growth of two strains of P. falciparum, one chloroquine-sensitive (F32/Tanzania) and 
other chloroquine-resistant (FcB1/Colombia) with IC50 1.48 and 1.2 μg/mL, respectively [51]. 
Cladocorans A and B, isolated from Cladocora caespitosa (order Scleractinia) [49], are marine 
sesterterpenoids which possess a γ-hydroxybutenolide moiety, which is thought to be responsible for 
the biological activity of these compounds. The potent anti-inflammatory activity of these natural 
metabolites was attributed to the inhibition of secretory phospholipase A2 (sPLA2, IC50 0.8–1.9 μM). 
Given the general role of inflammation in diseases that include bronchial asthma and rheumatoid 
arthritis, identifying and developing potent inhibitors of sPLA2 continues to be of great importance for 
the pharmaceutical industry, with this type of metabolite being of paramount importance for future 
research [50]. 
4. Class Hydrozoa 
Class Hydrozoa includes seven orders and nearly 3500 valid species (Table 1), some of which are 
solitary, some of which are colonial. Among the most emblematic species are probably hydroids and 
the Portuguese man-o-war (Physalia physalis). Despite the large number of species in class Hydrozoa, 
only a few of them have yielded interesting MNPs in the last decade. 
Immune escape plays an important role in cancer progression and, although not completely 
understood, it has been proposed that indoleamine 2,3-dioxygenase (IDO) plays a central role in 
evasion of T-cell-mediated immune rejection [157]. IDO catalyzes the oxidative cleavage of the  
2,3 bond of tryptophan, which is the first and rate-limiting step in the kynurenine pathway of 
tryptophan catabolism in mammalian cells [158]. The polyketides annulins A, B, and C, purified  
from the marine hydroid Garveia annulata (order Anthoathecata), potently inhibited IDO in vitro  
(Ki 0.12–0.69 μM) [159]. These annulins are more powerful than most tryptophan analogues known to 
be IDO inhibitors. These compounds are active at concentrations higher than ~10 μM and therefore 
more effective than 1-methyltryptophan (Ki 6.6 μM), one of the most potent IDO inhibitors currently 
available [160]. Solandelactones C, D, and G are cyclopropyl oxylipins isolated from the hydroid 
Solanderia secunda (order Anthoathecata) and exhibit moderate inhibitory activity against farnesyl 
protein transferase (FPT, 69, 89, and 61% inhibition, respectively) at a concentration of 100 μg/mL [161]. 
Note that FPT is associated with cell differentiation and proliferation and its inhibition may be a target 
for novel anticancer agents (as already referred above for the soft coral L. cristagalli). 
5. Class Scyphozoa 
Approximately 200 species are currently classified in three orders in class Scyphozoa (Table 1). 
However, in the last decade, only a single MNP purified from the mesoglea of the jellyfish 
Aurelia aurita (order Semaeostomeae) was considered to be promising enough to be included in the 
present work. This compound is a novel endogenous antibacterial peptide, aurelin, which exhibited 
activity against Gram-positive and Gram-negative bacteria. As an example, aurelin displayed an IC50 
of 7.7 µg/mL for Esherichia coli (Gram negative bacteria) [162]. 
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6. Other Classes 
The classes Staurozoa, Cubozoa and Polypodiozoa are the least speciose in the phylum Cnidaria 
(Table 1). This fact may explain the current lack of data on secondary metabolites produced by these 
organisms. It is possible that with growing bioprospecting new MNPs may be revealed once these 
cnidarian species are screened. Cubozoa (box jellies), for example, produce some of the most harmful 
cnidarian toxins for humans [163]. 
7. Exploring the Unexplored and Being Creative: Future Perspectives for the Bioprospecting  
of Cnidarians 
For several years, the bioprospecting of cnidarians was commonly limited to habitats that could be 
readily sampled by researchers, such as shallow coral reefs and the intertidal region. However, with 
improvements in SCUBA gear, researchers are now able to dive deeper and longer, allowing them to 
collect a wider range of cnidarian species for the screening of MNPs. The growing efforts to explore 
Earth’s last frontier, the deep sea, made it possible to start bioprospecting several unique marine 
ecosystems that had remained either previously unrecorded or inaccessible to researchers [164]. New 
cnidarian species (some of them belonging to new genera and probably even to new families)  
(e.g., [165,166]) are currently being sampled from the deep sea. These findings suggest that many new 
species are yet to be discovered along deep continental margins [167] and open good perspectives for 
the discovery of new MNPs with ongoing surveys of deep sea fauna. Cnidarians are known to colonize 
unique deep sea biotopes, namely chemosynthetic sites (such as hydrothermal vents, cold seeps and 
whale falls [168]), as well as seamounts [169]. Some of these organisms are endemic to these habitats 
and display remarkable adaptations to extreme environments (e.g., chemosynthetic sea anemones) [170]. 
These species are certainly interesting candidates for the discovery of new MNPs [171]. However, 
some of these remarkable biotopes, namely deep sea coral reefs, are already facing serious threats to 
their conservation [169] and thus, the bioprospecting of these and other endangered habitats must be 
carefully addressed [164,172]. 
Another interesting source of cnidarian species for bioprospecting is the marine aquarium industry. 
Over 200 species of hard and soft corals, along with several other anemone, zoanthid and corallimorph 
species, are harvested every year from coral reefs to supply the marine aquarium trade [173]. However, 
researchers using these organisms in the bioprospecting of new MNPs must be aware that it is not 
commonly possible to get reliable information on either the place of origin or the scientific name of 
most traded specimens. With the advent of high-throughput screening (HTS) [174], it will be possible 
to rapidly survey these organisms for interesting MNPs, although HTS of natural sources may present 
several challenges (see [175,176]). If necessary, additional biomass of target organisms producing 
interesting MNPs can be achieved using inexpensive techniques [177,178] and eliminate problems 
commonly faced by researchers screening marine organisms for MNPs–the loss of the source and 
reproducibility [176].  
The discovery of a new compound commonly requires only small amounts of biomass. However 
the production of these compounds at a scale large enough to fulfill commercial applications is still 
nearly impossible [179]. In theory, large-scale production of bioactive compounds can be achieved by 
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chemical synthesis or through extraction from marine animals, either harvested from the sea or 
maricultured. The existence of ecophysiological diversity (e.g., differences between individuals often 
due to differences in environmental interactions) can interfere with the production of MNPs and must 
be carefully addressed in future efforts for large-scale production of these compounds. The harvest of 
target animals from the wild for the production of chemical compounds is commonly an unsustainable 
solution, while mariculture has proven to be more technically challenging and expensive than 
previously assumed [180]. In other considerations, chemical synthesis is not yet developed to 
synthesize complex molecules at the kilogram scale and, in cases where this may already be 
technically possible, most of the compounds cannot be synthesized at a price affordable for 
commercial applications [179]. Potential solutions for such bottlenecks may be the use of diverted total 
synthesis [181] and/or metabolic engineering [182]. 
There is growing evidence that microbes associated with marine invertebrates may be the true 
producers of some of the bioactive compounds isolated from these animals [179]. Whether this is the case 
of bioactive compounds currently assumed to be produced by cnidarians remains unanswered [183,184]. 
If so, we face another constraint for the commercial use of these compounds, as the culture of 
symbiotic microorganisms is generally not possible using classic/standardized methodologies. 
8. Conclusions 
The intense pressure to find and develop more profitable molecules for all sorts of industries 
continues to fuel the bioprospecting of marine invertebrates. Although the phylum Cnidaria is not the 
most significantly bioprospected at present, this review shows that some cnidarian species are 
promising sources of marine bioactive compounds of medical, economic and scientific interest. Green 
fluorescent protein (GFP), GPF-like proteins, red fluorescent and orange fluorescent protein (OPF) are 
good examples of biotechnological metabolites currently employed as molecular biomarkers. They 
were first purified from a fluorescent hydrozoan medusa [185] and since then have been recorded in 
other cnidarian species [186–191]. 
In the present survey, only about 0.31% of extant cnidarian species are represented, with class 
Anthozoa displaying by far the highest number of promising MNPs (Figure 2). This result is probably 
due to the fact that this class is the most speciose in the phylum (Table 1). Additionally, many 
anthozoans occupy marine habitats which can be readily accessed for the collection of biomass  
(e.g., coral reefs and intertidal regions), which facilitates bioprospecting. Of all the compounds 
presented in this review, 84% were detected in cnidarians collected from tropical waters (mostly from 
Southeast Asia and the Caribbean Sea) and the remaining 16% were recorded from species mostly 
occupying temperate waters (e.g., European countries and Japan).  
Antitumor drugs are the main area of interest in the screening of MNPs from cnidarians  
(41%, Figure 3). This is not surprising, as the major financial effort for the screening of new marine 
compounds is made in cancer research [192]. Terpenoids (terpenoid, diterpenoid, sesquiterpenoid, 
sesterterpenoid, cembranoid) [193] (Figure 4) are the main chemistry group within the MNPs analyzed 
in this survey. 
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Figure 2. Marine bioactive compounds with high biotechnological potential studied from 
the phylum Cnidaria in the last decade. 
 
Figure 3. Distribution in drug classes of marine bioactive compounds with high 
biotechnological potential studied from cnidarian species in the last decade. 
 
Figure 4. Distribution of chemistry classes of marine bioactive compounds with high 
biotechnological potential studied from cnidarian species in the last decade. 
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Even though most pharmaceutical industries abandoned their natural product-based discovery 
programs over a decade ago, the lack of new compounds in their pipelines in some strategic areas  
(e.g., antibiotics) suggests that renewed interest in this field is imminent. The establishment of small 
biotech companies can play a decisive role in the initial discovery of promising marine bioactive 
compounds, as these enterprises will work closely together with academics and governmental agencies 
performing the initial steps in the discovery of new MNPs. Collaboration between private companies 
and public institutions can be of paramount importance for financial support in the discovery process. 
On the other side, crude extracts and pure compounds produced by academic laboratories may be 
screened by diverse bioassays as a part of broader collaboration programs, nationally and 
internationally, with private biotech companies. One challenge for universities is to devise mechanisms 
that protect intellectual property and simultaneously encourage partnerships with the private sector, by 
recognizing that the chances of a major commercial pay-off are small if drug discovery is pursued by a 
single institution [3]. 
The commercial use of some promising marine bioactive compounds isolated from cnidarians may 
be several years away. New compounds other than toxins and venoms produced by members of this 
highly diverse group of marine invertebrates may be discovered in the quest for new marine products. 
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